| Leukemia, Myelocytic, Acute
Daurismo vs Rezlidhia
Side-by-side clinical, coverage, and cost comparison for leukemia, myelocytic, acute.Deep comparison between: Daurismo vs Rezlidhia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRezlidhia has a higher rate of injection site reactions vs Daurismo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rezlidhia but not Daurismo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Daurismo
Rezlidhia
At A Glance
Oral
Daily
Hedgehog pathway inhibitor
Oral
Twice daily
IDH1 inhibitor
Indications
- Leukemia, Myelocytic, Acute
- Leukemia, Myelocytic, Acute
Dosing
Leukemia, Myelocytic, Acute 100 mg orally once daily on days 1-28 in combination with cytarabine 20 mg subcutaneously twice daily on days 1-10 of each 28-day cycle; treat for a minimum of 6 cycles in the absence of unacceptable toxicity or loss of disease control.
Leukemia, Myelocytic, Acute 150 mg orally twice daily until disease progression or unacceptable toxicity; take on an empty stomach at least 1 hour before or 2 hours after a meal.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Anemia, hemorrhage, febrile neutropenia, thrombocytopenia, fatigue, edema, mucositis, pyrexia, chest pain, musculoskeletal pain, muscle spasm, nausea, constipation, abdominal pain, diarrhea, vomiting, dyspnea, cough, decreased appetite, dysgeusia, dizziness, headache, rash, pneumonia, hyponatremia, platelet count decreased, weight decreased, white blood cell count decreased, atrial arrhythmia, renal insufficiency
Serious (>=5%) Febrile neutropenia, pneumonia, hemorrhage, anemia, sepsis
Most common (>=20%) AST increased, ALT increased, potassium decreased, sodium decreased, alkaline phosphatase increased, nausea, creatinine increased, fatigue/malaise, arthralgia, constipation, lymphocytes increased, bilirubin increased, leukocytosis, uric acid increased, dyspnea, pyrexia, rash, lipase increased, mucositis, diarrhea, transaminitis
Serious Differentiation syndrome, transaminitis
Pharmacology
Glasdegib is a Hedgehog pathway inhibitor that binds to and inhibits Smoothened, a transmembrane protein involved in hedgehog signal transduction, and exhibits concentration-dependent QTc prolongation.
Olutasidenib is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1); it inhibits mutant IDH1 proteins (R132H, R132C, and others), reducing 2-hydroxyglutarate (2-HG) levels in leukemia cells and promoting differentiation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Daurismo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (4/12) · Qty limit (11/12)
Rezlidhia
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Daurismo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Rezlidhia
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Daurismo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Rezlidhia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Acute Myeloid Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$15/fillfill
Rezlidhia CoPay AssistanceCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DaurismoView full Daurismo profile
RezlidhiaView full Rezlidhia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.